Buprenorphine and Piritramide: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Piritramide
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both of these are strong opioids. Buprenorphine is used for pain or opioid dependence, and piritramide is a powerful pain medicine given in some hospitals. Taking them together adds up their effects on your brain and breathing. That can make you very drowsy, slow your breathing, and in serious cases lead to dangerously deep sedation.
There is also a chance of a reaction called serotonin syndrome, which can cause agitation, a racing heart, sweating, shaking, or confusion. The good news is your care team can manage this. They may adjust doses, use the lowest amount that works, or watch you closely. Never change either medicine on your own, but do tell your doctor or pharmacist right away if you feel unusually sleepy or short of breath.
Interaction: Additive CNS and respiratory depression plus increased serotonin syndrome risk when buprenorphine is combined with piritramide (an opioid analgesic).
- Mechanism: Additive opioid/serotonergic CNS depression; both are active drugs (not prodrugs requiring bioactivation for this effect).
- Direction: Increased effect, risk of profound sedation, respiratory depression, coma, death.
- Evidence: Probable. Severity: Major. Onset: Unspecified.
- Management: Avoid concurrent use where possible. If required, use lowest effective doses and monitor sedation, respiratory rate/oxygenation, and serotonin syndrome signs, especially at initiation and dose changes. Consider higher level of care. Discontinue buprenorphine if serotonin syndrome is suspected.
What happens
An increased risk of serotonin syndrome and an increased risk of respiratory and CNS depression
Interaction Deep Dive
When buprenorphine is given together with a serotonergic CNS depressant, the effects on the central nervous system may be additive, raising the likelihood of serotonin syndrome as well as respiratory depression, deep sedation, coma, and death. Rather than using these agents together, discontinuing the other CNS depressant is the preferred approach. Depending on the situation, it may be suitable to monitor the patient at a higher level of care or to pursue a taper. In other circumstances, slowly tapering a patient off a prescribed benzodiazepine or another CNS depressant, or reducing the dose to the lowest effective amount, may be appropriate. Should combined use be required, watch for sedation, respiratory depression, and the signs and symptoms of serotonin syndrome. Observe the patient closely, especially when therapy is being started and while the dose of the serotonergic drug is being adjusted. If serotonin syndrome is suspected, stop buprenorphine, and consider alternative treatments for anxiety or insomnia21.
Why it happens (mechanism)
Additive serotonergic effects; additive CNS and respiratory depression
How to manage this interaction
Keep taking both exactly as prescribed unless your care team tells you otherwise. This combination is usually avoided, but when both are needed, teams manage it carefully.
- Your care team may use the lowest effective doses and adjust them, individualized to you.
- They may monitor you more closely for sedation and slow breathing, especially when starting or changing doses.
- Care in a higher-monitoring setting may be appropriate in some cases.
Get help right away if you notice heavy drowsiness, slow or shallow breathing, confusion, agitation, fast heartbeat, sweating, or shaking. Ask your pharmacist or prescriber before making any change.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
2 reports — tap to read
a) A Swedish epidemiological study reported that patients receiving methadone- or buprenorphine-based medication-assisted treatment (MAT) together with benzodiazepines or other CNS depressants (for example, drugs used to treat insomnia) have an increased risk of death. From July 1, 2005 to December 31, 2012, the risk of fatal overdose, non-overdose related mortality, and all-cause mortality was analyzed in MAT prescribed patients (aged 18 to 50), comparing periods when CNS depressants were prescribed to periods without CNS depressant therapy. The findings showed an increased risk of all-cause mortality (adjusted hazard ratio (HR) 1.44; 95% CI, 0.93 to 2.23) and non-overdose related mortality (HR 1.74; 95% CI 1.00 to 3.01) with MAT and benzodiazepine treatment; however, this data was not considered statistically significant. Although the results showed an increased risk of fatal overdose, non-overdose mortality, and all-cause mortality during periods of coadministration of MAT and non-benzodiazepines, only the data for fatal overdose and all-cause mortality was considered statistically significant; HR 2.34 (95% CI, 1.37 to 3.99) and HR 1.33 (95% CI, 1.12 to 2.45), respectively. A comparison between the benzodiazepine cohort and the non-benzodiazepine cohort was not performed because the authors did not adjust for the indication of use for the drugs 3.
b) According to a study of aggregate nationwide death certificate data from 2010 to 2014, 3495 drug overdose deaths were reported in 2014. Methadone and other CNS depressants were commonly cited as responsible for those deaths. Concurrent use of alprazolam was reported in 18.1% of cases, followed by oxycodone (10.1%), cocaine (9.6%), heroin (9%), and diazepam (6.6%). The FDA reported 322 drug overdose deaths in 2014 that involved buprenorphine. Among these 322 deaths, 32.9% involved alprazolam, 17.4% involved clonazepam, 11.2% involved diazepam, 11.2% involved heroin, and 9.9% involved fentanyl. The absolute number of deaths involving methadone was 10 times the number involving buprenorphine, though confounding factors and differences in drug utilization were not taken into account. Whether the risk of overdose death with concomitant CNS depressant drugs differed between buprenorphine and methadone is unknown 3.
Common questions
Can I take Buprenorphine and Piritramide together?
Combining buprenorphine and piritramide adds opioid effects and can cause dangerous sedation, slowed breathing, and a risk of serotonin syndrome, so this pairing is usually avoided. If both are prescribed, take them as directed, expect close monitoring, and seek help immediately for extreme drowsiness or trouble breathing. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Piritramide interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Piritramide interaction managed?
Keep taking both exactly as prescribed unless your care team tells you otherwise. This combination is usually avoided, but when both are needed, teams manage it carefully. Your care team may use the lowest effective doses and adjust them, individualized to you. They may monitor you more closely for sedation and slow breathing, especially when starting or changing doses. Care in a higher-monitoring… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Buprenorphine or Piritramide need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: SUBUTEX(R) sublingual tablets, buprenorphine sublingual tablets. Indivior Inc (per FDA), North Chesterfield, VA, 2021. DailyMed
- US Food and Drug Administration (FDA): Drug Safety Communications: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. US Food and Drug Administration (FDA). Silver Spring, MD. 2017.
Keep reading about Buprenorphine
Keep reading about Piritramide
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist